Dianthus Therapeutics (DNTH) Stock Overview
A clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
DNTH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Dianthus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$82.49 |
| 52 Week High | US$96.50 |
| 52 Week Low | US$16.64 |
| Beta | 0.066 |
| 1 Month Change | -7.02% |
| 3 Month Change | 6.08% |
| 1 Year Change | 389.41% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 649.91% |
Recent News & Updates
Dianthus Therapeutics (DNTH) Stock After CAPTIVATE Results Looks Fairly Valued
Dianthus Therapeutics (DNTH) drew fresh attention after reporting positive midstage results from its CAPTIVATE Phase 3 trial in chronic inflammatory demyelinating polyneuropathy, highlighting a high confirmed responder rate along with a favorable safety profile. See our latest analysis for Dianthus Therapeutics. The CAPTIVATE data arrived after a strong run in Dianthus Therapeutics, with the share price at $78.88 and a year to date share price return of 98.79%. Short term momentum has cooled,...Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
Summary Dianthus Therapeutics is positioned as a category-expanding biotech, leveraging convenience and safety to address autoimmune neuromuscular and rheumatology markets. DNTH boasts a robust balance sheet with over $1 billion in cash and investments, ensuring operational runway through 2030 and strategic independence post-positive clinical data. Claseprubart’s promising efficacy and safety in gMG, CIDP, and MMN, alongside the DNTH212 rheumatology franchise, underpin a multi-pronged growth thesis with major catalysts in late 2026. Valuation is driven by optionality from a well-funded pipeline, but key risks remain in Phase 3 trial translation and competitive differentiation against established players. Read the full article on Seeking AlphaRecent updates
Shareholder Returns
| DNTH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.5% | 1.3% | 1.7% |
| 1Y | 389.4% | 31.1% | 25.1% |
Return vs Industry: DNTH exceeded the US Biotechs industry which returned 30.5% over the past year.
Return vs Market: DNTH exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| DNTH volatility | |
|---|---|
| DNTH Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DNTH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DNTH's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 92 | Marino Garcia | dianthustx.com |
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Dianthus Therapeutics, Inc. Fundamentals Summary
| DNTH fundamental statistics | |
|---|---|
| Market cap | US$4.51b |
| Earnings (TTM) | -US$173.66m |
| Revenue (TTM) | US$1.34m |
Is DNTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DNTH income statement (TTM) | |
|---|---|
| Revenue | US$1.34m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.34m |
| Other Expenses | US$175.00m |
| Earnings | -US$173.66m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.18 |
| Gross Margin | 100.00% |
| Net Profit Margin | -12,998.50% |
| Debt/Equity Ratio | 0% |
How did DNTH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/19 01:37 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dianthus Therapeutics, Inc. is covered by 18 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Colleen Kusy | Baird |
| null null | Baird |